Perrigo’s First National Brand, Nasonex OTC Switch, Will Have Familiar Buzz In Advertising

Firm to promote Nasonex 24HR Allergy nasal spray with cartoon bee familiar with brand’s marketing as an Rx product. It doesn't anticipate receiving OTC market exclusivity along with approval of first OTC mometasone furoate product in US.

The cartoon bee familiar from advertising for Rx Nasonex will be used for Perrigo's OTC switch with the same formulation. • Source: Alamy

Perrigo Company PLC’s first US OTC switch, also its first national branded product, will have a familiar look in advertising and marketing.

It will promote Nasonex 24HR Allergy nasal spray with the cartoon bee familiar with the brand’s marketing as an Rx...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rx-to-OTC Switch

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By 

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.

Haleon Study: Self-Care Policies Could Save Finland €60m Per Year

 
• By 

Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.

PAGB: UK Gov Must Invest In Self-Care To Realize ‘Untapped Potential’

 
• By 

Reacting to chancellor Rachel Reeves' 2025 public spending review, PAGB welcomed increased funding for healthcare and life sciences while stressing the need to promote self-care practices.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By 

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

More from Health

People On The Move: Appointments At Opella, Stada, Futura

 
• By 

Latest European appointments: Opella names Germany director; Stada has new Western Europe head; Futura makes CEO change.

House OMUFA Reauthorization Bill Takes On Clarifying Standards For Tests To Meet GRASE

 

Health Subcommittee will discuss reauthorizing OMUFA during a hearing on how to “maintain and improve” the public health workforce and rural health as well as access to OTC medicines.

Kenvue Makes CEO Change Months After Critical Activist Investor Made Proxy Play For Board Seat

Thibaut Mongon is out as Kenvue CEO, a post he’s held since J&J spun it out in July 2023, after the firm’s results came under increased investor scrutiny over the past year. The board appointed as interim CEO Kirk Perry, a board member since December who most recently headed technology, data and pre